Saratoga Health & Biotechnology C holds a quantitatively derived Negative Morningstar Medalist Rating. The rating indicates the model sees limited potential for the strategy to outperform peers on a risk-adjusted basis over a full market cycle.
Saratoga Health & Biotechnology Portfolio Fund Class C SHPCX
- NAV / 1-Day Return 14.79 / −0.47 %
- Total Assets 11.2M
-
Adj. Expense Ratio
3.600%
- Expense Ratio 3.600%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Mid Value
- Min. Initial Investment 2,500
- Status Open
- TTM Yield 0.00
- Turnover 22%
USD | NAV as of Jul 11, 2026 | 1-Day Return as of Jul 11, 2026, 12:50 AM GMT+0
Morningstar’s Analysis SHPCX
Will SHPCX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Cardinal Health Inc | 6.44 | 674,827 | Healthcare |
Jazz Pharmaceuticals PLC | 6.19 | 648,219 | Healthcare |
United Therapeutics Corp | 6.16 | 645,911 | Healthcare |
Amgen Inc | 5.04 | 527,750 | Healthcare |
McKesson Corp | 4.90 | 513,026 | Healthcare |
Lantheus Holdings Inc | 4.64 | 486,570 | Healthcare |
Exelixis Inc | 4.55 | 476,784 | Healthcare |
Novartis AG ADR | 4.50 | 471,534 | Healthcare |
Cencora Inc | 4.33 | 453,333 | Healthcare |
Gilead Sciences Inc | 3.94 | 412,431 | Healthcare |